Related Experiment Videos
Investigational trials of anticancer drugs: establishing safeguards for experimentation
Abstract:
The National Cancer Institute since 1955 has been charged with responsibility for discovering new anti-cancer agents and bringing them to clinical trial. These activities are carried out by NCI's Developmental Therapeutics Program, which has established systems for discovery, experimental testing, bulk synthesis, formulation, and toxicological testing of candidate drugs, and by the Cancer Therapy Evaluation Program, which conducts initial trials to establish safe doses of new agents and to determine their utility in treating specific forms of cancer. These clinical trials are conducted both at NCI in Bethesda, Md., and at selected cancer centers throughout the United States. This paper describes the safeguards that NCI has built into the clinical trials system in the past decade-safeguards that ensure the safety of patients and the accuracy of data collected and at the same time allow efficient testing of each promising new agent in the fight against cancer. Recent improvements in cancer survival leave little doubt that patients are indeed benefiting from extensive efforts to discover and develop new drugs for cancer treatment.
Insights
The National Cancer Institute (NCI) has developed robust safeguards for cancer drug clinical trials. These systems ensure patient safety and data accuracy, leading to improved cancer survival rates.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Background:
- The National Cancer Institute (NCI) has a long-standing mission, dating back to 1955, to discover novel anti-cancer agents.
- This mission involves a comprehensive process from initial discovery through to clinical trials and evaluation.
Purpose of the Study:
- To describe the safeguards implemented by the NCI over the last decade to enhance its clinical trials system.
- To highlight how these safeguards ensure patient safety and data integrity while facilitating efficient drug development.
Main Methods:
- The NCI's Developmental Therapeutics Program manages drug discovery, preclinical testing, synthesis, formulation, and toxicology.
- The Cancer Therapy Evaluation Program conducts Phase I trials to determine safe dosages and therapeutic utility.
- Clinical trials are executed at NCI facilities and affiliated cancer centers across the United States.
Main Results:
- Implementation of enhanced safeguards within the NCI's clinical trials system over the past decade.
- These safeguards are designed to protect patient well-being and ensure the accuracy of collected data.
- The system allows for the efficient evaluation of promising new anti-cancer agents.
Conclusions:
- The NCI's structured approach and implemented safeguards have demonstrably contributed to advancements in cancer treatment.
- Recent improvements in cancer survival rates underscore the benefits of these extensive drug discovery and development efforts.